Fig 2: FLT3 inhibitor (quizartinib and gilteritinib) treatment suppresses CD155 and CD112 surface expression in acute myeloid leukemia cell lines with FLT3 mutations. Histograms of CD155 and CD112 expression in MOLM-13 and MV-4-11 cells treated with quizartinib or gilteritinib (1 and 10 nM: yellow and green, respectively)/DMSO (red) for 48 h. FLT3, FMS-like tyrosine kinase 3; MFI, mean fluorescence intensity.

Fig 3: MEK inhibitor (trametinib) suppresses CD155 and CD112 surface expression of most AML cell lines (MOLM-13, MV-4-11, THP-1, KG-1) examined. Histograms of CD155 and CD112 expression in AML cell lines treated with trametinib (10 and 100 nM: yellow and green, respectively)/DMSO (red) for 48 h. AML, acute myeloid leukemia; MFI, mean fluorescence intensity.

Fig 4: FLT3 inhibitor (quizartinib and gilteritinib) treatment does not suppress CD155 and CD112 surface expression in acute myeloid leukemia cell lines without FLT3 mutations. Histograms of CD155 and CD112 expression in THP-1, K562 and NB-4 cells treated with quizartinib or gilteritinib (1 and 10 nM: yellow and green, respectively)/DMSO (red) for 48 h. FLT3, FMS-like tyrosine kinase 3; MFI, mean fluorescence intensity.

Fig 5: Higher CD155 and CD112 mRNA expression is significantly associated with poor overall survival [n=162 (CD155/CD112 high group, n=11; and control group, n=151); P=0.0471].